Details of the Drug Combination

General Information of Drug Combination (ID: DCHZLU0)

Drug Combination Name
Pargyline Diethylcarbamazine
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Pargyline   DMM0HR1 Diethylcarbamazine   DM1TJ8F
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 36.96
Bliss Independence Score: 36.96
Loewe Additivity Score: 46.96
LHighest Single Agent (HSA) Score: 46.97

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pargyline
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [2]
Muscular dystrophy 8C70 Patented [3]
Skin imperfections EK71 Patented [3]
Pargyline Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Monoamine oxidase (MAO) TT32XQJ NOUNIPROTAC Inhibitor [3]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Pargyline Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Decreases Activity [6]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Decreases Activity [7]
------------------------------------------------------------------------------------
Indication(s) of Diethylcarbamazine
Disease Entry ICD 11 Status REF
Elephantiasis N.A. Approved [4]
Loiasis N.A. Approved [4]
Lymphatic filariasis 1F66.3 Approved [2]
Onchocerciasis 1F6A Approved [4]
Diethylcarbamazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Diethylcarbamazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Activity [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
4 Diethylcarbamazine FDA Label
5 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
6 Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. 2015 Mar 25;230:9-20.
7 Combining initro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration. Chem Biol Interact. 2016 Jul 25;254:135-45.
8 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
9 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.